Products Dihydroergocriptine is no longer registered in many countries. Cripar is out of commerce. Effects Dihydroergocriptine (ATC N04BC03) is dopaminergic and acts selectively on D2 receptors. It has no activity on serotoninergic or adrenergic receptors. Indications Parkinson’s disease Early stages of Parkinson’s disease, as monotherapy or in combination with an L-dopa preparation. Interval treatment of … Dihydroergocriptine
Products Quinagolide is commercially available in tablet form (Norprolac). It has been approved in many countries since 1994. Structure and properties Quinagolide (C20H33N3O3S, Mr = 395.56 g/mol) is a non-ergoline dopamine agonist with a similar structure to apomorphine. It is present in drugs as quinagolide hydrochloride. Effects Quinagolide (ATC G02CB04) has dopaminergic properties and inhibits … Quinagolide
Products Monk’s pepper extracts are commercially available as film-coated tablets and drops, among others. Stem plant Monk’s pepper L. belongs to the verbenaceae family. The shrub, which grows up to several meters high, is native to the Mediterranean region, Central Asia and India. Monk’s pepper has been used since ancient times to treat women’s ailments. … Monk Pepper
Products Amantadine is commercially available as film-coated tablets, capsules, and an infusion solution (Symmetrel, PK-Merz). It has been approved in many countries since 1966. Structure and properties Amantadine (C10H17N, Mr = 151.2 g/mol) is present in drugs as amantadine sulfate or amantadine hydrochloride. Amantadine hydrochloride is a white crystalline powder that is readily soluble in … Amantadine
Products In many countries, finished medicines containing cocaine are currently no longer commercially available. However, they can be prepared as an extemporaneous prescription in a pharmacy. Cocaine is subject to the Narcotics Act and requires an aggravated prescription, but it is not banned as a drug. It is also sold as an illegal narcotic on … Cocaine: Drug Effects, Side Effects, Dosage and Uses
Products Cabergoline is commercially available in tablet form (Cabaser, Dostinex). It has been approved in many countries since 1995. Structure and properties Cabergoline (C26H37N5O2, Mr = 451.6 g/mol) is a dopaminergic ergoline derivative. It exists as a white crystalline powder that is practically insoluble in water. Effects Cabergoline (ATC N04BC06) has dopaminergic properties and reduces … Cabergoline
Products Metergoline is commercially available in the form of tablets for animals. It has been approved in many countries since 1990. Structure and properties Metergoline (C25H29N3O2, Mr = 403.5 g/mol) is a synthetic ergoline derivative. Effects Metergoline (ATCvet QG02CB05) has antiserotoninergic properties and inhibits prolactin secretion. The effects are due to antagonism at serotonin 5HT … Metergolin
Products In many countries, there are no finished medicines containing amineptine on the market. Amineptin is one of the narcotics and requires an aggravated prescription. It was withdrawn from the market in France and other European countries in 1999 (Survector, Servier). Structure and properties Amineptine (C22H27NO2, Mr = 337.5 g/mol) belongs to the tricyclic antidepressants. … Amineptin
Effects The majority of antiparkinsonian drugs are directly or indirectly dopaminergic. Some are anticholinergic in action. Indications Parkinson’s disease, including drug-induced Parkinson’s disease in some cases. Drug treatment Overview of drug therapy: 1. dopaminergic agents Levodopa is a precursor of dopamine and is considered the most important and effective pharmacotherapy for PD. Combining it with … Antiparkinsonian
Products Bromocriptine is commercially available in tablet form (Parlodel). It was developed at Sandoz in the 1960s and has been approved in many countries since 1975. Generic versions are now available in many countries. Structure and properties Bromocriptine (C32H40BrN5O5, Mr = 654.6 g/mol) is a brominated derivative of the natural ergot alkaloid ergocryptine. It is … Bromocriptine
Products Uprima sublingual tablets (2 mg, 3 mg) for erectile dysfunction are no longer marketed in many countries. The marketing authorization was not renewed by Abbott AG in 2006. Commercial reasons were cited, probably attributed to competition from phosphodiesterase-5 inhibitors (e.g., sildenafil, Viagra). It is also possible that a post-marketing study had played a role, … Apomorphine
Effects Indirect dopaminergic Indications Parkinson’s disease Depression (USA) Active ingredients Rasagiline (Azilect) Selegiline (off label) Safinamide (Xadago)
